STOCK TITAN

Rapport Therapeutics (RAPP): Capital International Investors reports 6.1% beneficial stake

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Capital International Investors, a division of Capital Research and Management Company and its investment management affiliates, reports amended beneficial ownership of common stock of Rapport Therapeutics, Inc..

CII is deemed to beneficially own 2,921,958 shares of Rapport Therapeutics common stock, representing 6.1% of the class, based on 47,826,929 shares believed to be outstanding. CII reports sole voting and sole dispositive power over 2,921,958 shares and no shared voting or dispositive power. The filing identifies SMALLCAP World Fund, Inc. as a person with rights to receive dividends or sale proceeds related to these securities.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 2,921,958 shares Common stock of Rapport Therapeutics beneficially owned by Capital International Investors
Percent of class 6.1% Portion of Rapport Therapeutics common stock class beneficially owned
Shares outstanding baseline 47,826,929 shares Shares of Rapport Therapeutics common stock believed to be outstanding
Sole voting power 2,921,958 shares Shares for which Capital International Investors has sole power to vote
Sole dispositive power 2,921,958 shares Shares for which Capital International Investors has sole power to dispose
Amendment date 06/30/2026 Dated as of June 30, 2026 in the Schedule 13G/A
beneficial owner financial
"CII is deemed to be the beneficial owner of 2,921,958 shares"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
sole voting power financial
"Sole power to vote or to direct the vote: 2,921,958"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power financial
"Sole power to dispose or to direct the disposition of: 2,921,958"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
percent of class financial
"Percent of class: 6.1 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
Schedule 13G/A regulatory
"Capital International Investors files on Schedule 13G/A as a holder over 5%"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What percentage of Rapport Therapeutics (RAPP) does Capital International Investors report owning?

Capital International Investors reports beneficial ownership of 6.1% of Rapport Therapeutics’ common stock, corresponding to 2,921,958 shares, based on 47,826,929 shares of common stock believed to be outstanding at the time of the filing.

How many Rapport Therapeutics (RAPP) shares does Capital International Investors control voting for?

Capital International Investors reports sole voting power over 2,921,958 shares of Rapport Therapeutics common stock and no shared voting power, indicating it alone can vote or direct the voting of these reported shares.

Who is the reporting person in this Schedule 13G/A for Rapport Therapeutics (RAPP)?

The reporting person is Capital International Investors, a division of Capital Research and Management Company and its investment management subsidiaries and affiliates, collectively providing investment management services under the Capital International Investors name.

What is the total number of Rapport Therapeutics (RAPP) shares outstanding used in this ownership calculation?

Capital International Investors’ 6.1% ownership is calculated using 47,826,929 shares of Rapport Therapeutics common stock that are believed to be outstanding, serving as the denominator for the reported percentage of the class.

Does any other party have rights to dividends or sale proceeds on the Rapport Therapeutics (RAPP) shares?

Yes. The filing identifies SMALLCAP World Fund, Inc. as a person that has the right to receive dividends from, or the proceeds from the sale of, the reported Rapport Therapeutics securities held on its behalf.

What dispositive power over Rapport Therapeutics (RAPP) shares does Capital International Investors report?

Capital International Investors reports sole dispositive power over 2,921,958 shares of Rapport Therapeutics common stock and no shared dispositive power, meaning it alone can decide how and when to dispose of these shares.





75383L102

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



Capital International Investors
Signature:Aaron Espin
Name/Title:Senior Vice President
Date:07/29/2026